Aurobindo Pharma Limited’s wholly owned subsidiary, Eugia Pharma Specialities Limited, has received a final approval from the US Food & Drug Administration (USFDA) for its Lenalidomide Capsules.
The capsules are available in six different strengths ranging from 2.5 mg to 25 mg, and are bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Revlimid Capsules, of Bristol-Myers Squibb Company. The company plans to launch the product in October 2023, with a volume-specific launch.
This is the 155th ANDA approval for Eugia Pharma Speciality Group, which manufactures both oral and sterile specialty products, including the newly approved product. Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone.
About Eugia Pharma:
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
For More Latest News Click Here